Close menu




July 16th, 2026 | 07:10 CEST

Evotec Shocks the Market! Will First Majestic Silver and Lahontan Gold Take Off?

  • Mining
  • Gold
  • Silver
  • Commodities
  • Nevada
  • Biotechnology
Photo credits: AI

Biotech stocks have not exactly been investor favourites this year. And now Evotec has delivered yet another shock. It was already known that the company was undergoing a comprehensive restructuring. Nevertheless, it had recently seemed as though the share price was finding a bottom in the EUR 4-5 range. But then came the shock. The significant downward revision of its forecast and the expected high EBITDA loss caused the share price to plummet. In contrast, Lahontan Gold is shining with relative strength. While it cannot escape the negative sentiment in the gold sector, the odds are good that the share price will take off again soon. After all, the company is on the verge of transitioning from an explorer to a producer. And what about First Majestic Silver? This core investment in the silver sector recently reported its second-quarter production figures.

time to read: 5 minutes | Author: Fabian Lorenz
ISIN: LAHONTAN GOLD CORP | CA50732M1014 | TSXV: LG , OTCQB: LGCXF , EVOTEC SE INH O.N. | DE0005664809 , FIRST MAJESTIC SILVER | CA32076V1031

Table of contents:


    Lahontan Gold: First Relative Strength, Then Outperformance?

    Lahontan Gold offers attractive exposure to the gold price. The company is developing a comparatively low-risk gold production project in the US state of Nevada. The focus is on the historic Santa Fe Mine. According to management's plans, it is set to resume gold production as early as next year. CEO and founder Kimberly Ann highlights in particular the manageable capital requirements, low production costs, and a short payback period. The current resource totals a robust 2 million metric tons of gold equivalent. At the same time, the nearby West Santa Fe satellite project opens up additional growth potential. And then there are the historic heap leach pads, which management estimates could still contain more than 200,000 ounces of gold. Evaluation drilling is underway.

    The application for the mine is scheduled to be submitted in the first quarter of 2027. Once all permits are in place, the mine is expected to be operational within just four to six months. The company benefits from its location: the 28.3 km² Santa Fe mine is situated within the Walker Lane Trend, one of the world's premier mining regions.

    Production costs for the Santa Fe project are currently estimated at around USD 1,200 per ounce. It is no surprise, then, that founder and CEO Kimberly Ann has repeatedly pointed out that the company will "make a lot of money" once production begins. The planned financing also appears to be relatively manageable. Approximately USD 135 million is estimated for the ramp-up to production. The short payback period is particularly crucial for Kimberly Ann. She expects the invested capital to be recouped within 12 to 18 months. Given this profile, the CEO confidently asks, "Who wouldn't give us money for this?" The low production costs and expected cash flows could enable Lahontan Gold to repay the debt used for mine construction unusually quickly.

    Lahontan's stock has been trading sideways since mid-March, demonstrating relative strength compared to the gold price and gold stocks. If sector sentiment improves, Lahontan is a strong candidate for outperformance.

    https://youtu.be/QGRV7IfTWec?si=GHVNPooFwSnStJ6n

    Evotec Shocks the Stock Market

    Like gold and silver, the biotech sector is currently not a focus for investors. BioNTech and Evotec are prime examples of this. BioNTech had already spooked investors with announced plant closures. It was known that Evotec was undergoing a comprehensive restructuring. Nevertheless, it had recently appeared that the stock was finding a bottom in the EUR 4-5 range. Since Monday, however, this technical picture has become obsolete. The significant downward revision of the forecast and the expected high EBITDA loss have once again significantly intensified the downward pressure.

    Following a weak first half of the year, Evotec has significantly lowered its outlook for 2026. Preliminary figures show the group generated revenue of approximately EUR 300.1 million and an adjusted EBITDA of minus EUR 42.7 million. For the full year, Evotec now expects revenue of only EUR 570-610 million and an adjusted EBITDA of EUR -70 to -105 million. Previously, the company had anticipated revenue of EUR 700-780 million and adjusted EBITDA of EUR 0-40 million. The main reasons are deferred milestone payments from existing partnerships and delays in new strategic collaborations. Approximately 40% of the revenue shortfall is expected to be deferred to 2027, while another 45% is attributable to partnerships that were concluded later than expected.

    By contrast, the core business is performing well. Net sales in the Discovery & Preclinical Development segment rose by approximately 28% in the first half of the year. Evotec Biologics benefited from high capacity utilization and a growing customer base. In addition, the company reports that the Horizon transformation program is on track. Evotec aims to achieve 20% to 30% of the EUR 75 million in total cost savings targeted by the end of 2027 as early as 2026. CEO Christian Wojczewski emphasized that the downward revision of the forecast was primarily due to timing shifts and did not represent a reassessment of the long-term potential of the partner pipeline. Investors nevertheless reacted with shock.

    First Majestic Silver: Will Production Figures Provide New Momentum?

    First Majestic Silver's stock is also struggling at the moment. Although the share is still up about 11% for the current year, it was already trading above EUR 28 at the end of February. It currently stands at just under EUR 15.

    Production figures for the second quarter of 2026 also failed to provide new momentum. Yet the operational performance was solid. Proportional silver production rose 3% year-over-year to 3.8 million ounces, while gold production increased by 2% to 34,660 ounces. In addition, the company produced 16.5 million pounds of zinc, 9.0 million pounds of lead, and approximately 253,000 pounds of copper. Santa Elena and La Encantada performed particularly well. CEO Keith Neumeyer spoke of another strong quarter. He emphasized that the company was able to make up for a large portion of the lost time despite work interruptions at San Dimas and a minor rockfall at Los Gatos.

    First Majestic is also making progress on its growth projects. According to the company, the expansions of the processing facilities at Santa Elena and Los Gatos are on schedule and are expected to be completed in the third quarter. At Santa Elena, building permits for the Santo Niño and Navidad portals were also granted earlier than expected. Additional investments of USD 12 million are planned for further development in 2026. At the same time, the formerly active Del Toro mine was sold to Sierra Madre for consideration of up to USD 60 million, of which USD 30 million was paid as an upfront payment.

    Due to its strong performance in the first half of the year, First Majestic has raised its production forecast for 2026. The company now expects to produce 14.6 to 15.5 million ounces of silver, up from the previous forecast of 13.0 to 14.4 million ounces, as well as 128,000 to 135,000 ounces of gold, up from 116,000 to 129,000 ounces. Forecasts for Santa Elena, Los Gatos, San Dimas, and La Encantada have also been raised. At the same time, the capital budget is increasing to USD 318–344 million, partly to fund the restart of Jerritt Canyon and other expansion projects.


    Lahontan Gold has several potential catalysts for its share price. First and foremost, of course, is the start of production next year. Combined with low production costs, this should generate strong cash flows. In addition, the resource estimate could be further increased. And in the coming months, drill results could trigger sharp price jumps. First Majestic remains a core investment in the silver sector. If the silver price rises again, the stock should be able to gain disproportionately. At Evotec, the new management has now also disappointed market expectations. The stock is unlikely to recover from this anytime soon.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Nico Popp on July 16th, 2026 | 07:15 CEST

    Everyone Has to Pay—Why Investors Could Profit: The Toll Secret of InterDigital and AbbVie, Plus Globex Mining's Portfolio of 272 Resource Projects

    • royalties
    • Commodities
    • Digitization
    • patents

    The global economy is like a jungle, with toll booths waiting at every turn—anyone who wants to pass has to pay. A recent example is the rebranding of Siemens Energy to Omterra: even after being spun off from the Siemens Group, the company still has to pay for the right to use its former parent company's name. This toll-booth business model exists across many industries. Companies that own assets, technologies, or rights that others need can generate highly profitable, recurring revenue streams. We take a closer look at three compelling business models and highlight investment opportunities that could prove especially rewarding during periods of economic and technological transformation.

    Read

    Commented by André Will-Laudien on July 15th, 2026 | 11:00 CEST

    Sharp Swings in the Life Sciences Sector: Bayer, Vidac Pharma, BioNTech, Moderna, and Evotec in the Spotlight

    • Biotechnology
    • Biotech
    • Pharma
    • LifeSciences

    Things are really heating up here! Cancer research is currently undergoing a historic turning point thanks to the convergence of cell analysis and digital precision. With a new management team, BioNTech is attempting to transition its revolutionary mRNA platform from COVID-19 to personalized cancer vaccines, while Bayer is strategically focusing on next-generation targeted radionuclide therapies. In the agricultural sector, the first signs of relief are finally emerging, as glyphosate is now being negotiated at the supranational level and has been classified as non-harmful by US authorities. At the same time, drug discovery company Evotec is grappling with a new revenue warning—and this one is particularly severe. Vidac Pharma is also coming into focus as a highly specialized innovator by blocking cancer metabolism to decisively manipulate the tumour microenvironment. These four distinct approaches impressively demonstrate that the victory over cancer no longer lies solely in traditional chemotherapies, but rather in highly specialized biotech companies and data-driven alliances. With so much news on the table, volatility is sure to follow.

    Read

    Commented by Matthias Schomber on July 15th, 2026 | 08:45 CEST

    AI, Oncology, and Defense: TeamViewer, BioNTech, and Antimony Resources—A Great Mix for Your Portfolio!

    • antimony
    • CriticalMetals
    • Defense
    • Biotechnology
    • Oncology
    • AI

    Created and published on behalf of Antimony Resources Corp.

    The stock market is a place of extremes, and today we are looking at a trio—TeamViewer, BioNTech, and Antimony Resources—that comes from three different sectors. There is a German software pioneer that, after painful setbacks, is suddenly showing clear signs of life again. There is a once-celebrated vaccine hero pumping billions into a risky but revolutionary future in cancer therapy—while still holding a substantial cash reserve. And then there is a Canadian mineral explorer digging deep into the earth for a material without which our modern world would simply grind to a halt—one that is also crucial for the defense industry. It is precisely this mix of a software-AI turnaround, a biotech-oncology transformation, and mineral potential that makes the market so incredibly exciting. Join us on a journey through three fascinating corporate stories.

    Read